Abstract
Cytokine storm is the major cause of death in patients with acute respiratory distress caused by COVID-19. Because cytokine storm is a life-threatening condition, it is important to treat patients with the most appropriate drugs depending on their infectious pathogen and medical status. In this short review, we highlight the pharmacological and nonpharmacological options for handling the cytokine storm. The potential drug targets comprise the use of small molecule or large macromolecules. These molecules include antibodies to bind with and inhibit the actions of interleukins, cytokine signal transducers such as Janus Kinases (JAKs), and cytokine receptors such as the cytokine receptor colony-stimulating factor 1 receptor (CSF1R). So far, dexamethasone appeared to be the pharmacological treatment of choice in managing or preventing cytokine release syndrome because of its safety and cost-effectiveness. Other pharmacological options either require more studies to prove their efficacy (e.g., anakinra and solnatide) or have shown poor efficacy in recent studies (e.g., tocilizumab). Moreover, specific immunoadsorption techniques can be safe and effective when considering nonpharmacological treatment.
Article PDF
Avoid common mistakes on your manuscript.
References
Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012;76;16–32.
Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol 2012;5;134–41.
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci 2019;20;6008.
Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis 2018;24;2173–82.
Bahloul M, Ketata W, Lahyeni D, Mayoufi H, Kotti A, Smaoui F, et al. Pulmonary capillary leak syndrome following COVID‐19 virus infection. J Med Virol 2021;93;94–6.
Xie Z, Ghosh CC, Patel R, Iwaki S, Gaskins D, Nelson C, et al. Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome). Blood 2012;119;4321–32.
Saly DL, Perazella MA. Adverse kidney effects of immunotherapies. In: Finkel KW, Perazella MA, Cohen EP, editors. Onconephrology. Amsterdam: Elsevier; 2020, pp. 166.e3–82.e3.
Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2013;27;669–84.
Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nat Rev Immunol 2020;20;271–2.
Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol 2018;9;1157.
Wampler Muskardin TL. Intravenous Anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of coronavirus disease 2019. ACR Open Rheumatol 2020;2;283–5.
Starobova H, Monteleone M, Adolphe C, Batoon L, Sandrock CJ, Tay B, et al. Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release. J Exp Med 2021;218;e20201452.
Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 2014;66;3227–32.
van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care 2020;24;445.
Monteagudo LA, Boothby A, Gertner E. Continuous intravenous Anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol 2020;2;276–82.
Nemchand P, Tahir H, Mediwake R, Lee J. Cytokine storm and use of anakinra in a patient with COVID-19. BMJ Case Rep 2020;13;e237525.
Pawar A, Desai RJ, Solomon DH, Ortiz AJS, Gale S, Bao M, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis 2019;78;456–64.
Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int J Mol Sci 2020;21;3330.
Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021;384;1503–16.
Salama C, Mohan SV. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021;384;1473–4.
Russell B, Moss C, George G, Santaollala A, Cope A, Papa S, et al. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecancermedicalscience 2020;14;1022.
INB03 for the treatment of pulmonary complications from COVID-19. Available from: https://https://clinicaltrials.gov/ct2/show/NCT04370236. U.S. National Library of Medicine (accessed April 3, 2021).
Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018;41;489–509.
Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother 2017;13;2247–59.
Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Dev Ther 2018;12;3879–83.
A study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome secondary to COVID-19 (BREATHE). Available from: https://clinicaltrials.gov/ct2/show/NCT04351243. U.S. National Library of Medicine (accessed April 3, 2021).
A phase 2 study to evaluate axatilimab for hospitalized patients with respiratory involvement secondary to COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04415073?term=Axatilimab&draw=2&rank=2. U.S. National Library of Medicine (accessed April 3, 2021).
Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94;557–72.
Tufan A, Güler AA, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020;50;620–32.
Abdullah A, Mahmoud K. Dexamethasone as a treatment of COVID-19. Dr Sulaiman Al Habib Med J 2021;3;7–9.
Alcock J, Masters A. Cytokine storms, evolution and COVID-19. Evol Med Public Health 2021;9;83–92.
Águas R, Mahdi A, Shretta R, Horby P, Landray M, White L, et al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun 2021;12;915.
Wise J. Covid-19: arthritis drugs improve survival in intensive care patients, shows study. BMJ 2021;372;n61.
Tzotzos S, Fischer B, Fischer H, Pietschmann H, Lucas R, Dupré, et al. AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulmon Pharmacol Ther 2013;26;356–63.
Hanukoglu I, Hanukoglu A. Epithelial sodium channel (ENaC) family: phylogeny, structure-function, tissue distribution, and associated inherited diseases. Gene 2016;579;95–132.
Zhou Q, Wang D, Liu Y, Yang X, Lucas R, Fischer B. Solnatide demonstrates profound therapeutic activity in a rat model of pulmonary edema induced by acute hypobaric hypoxia and exercise. Chest 2017;151;658–67.
Lucas R. Solnatide: tackling pulmonary permeability edema from all angles. Clin Exp Pharmacol 2018;8;42.
Gröger M, Pasteiner W, Ignatyev G, Matt U, Knapp S, Atrasheuskaya A, et al. Peptide Bβ15–42 preserves endothelial barrier function in shock. PLoS One 2009;4;e5391.
Wallez Y, Cand F, Cruzalegui F, Wernstedt C, Souchelnytskyi S, Vilgrain I, et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 2007;26;1067–77.
Koziolek MJ, Tampe D, Bähr M, Dihazi H, Jung K, Fitzner D, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 2012;9;80.
Baggi F, Ubiali F, Nava S, Nessi V, Andreetta F, Rigamonti A, et al. Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. J Neuroimmunol 2008;201;104–10.
Hamilton P, Harris R, Mitra S. Immunoadsorption techniques and its current role in the intensive care unit. In: Karkar A, editor. Aspects in continuous renal replacement therapy. IntechOpen 2019.
Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007;28;418–25.
Yiğenoğlu TN, Ulas T, Dal MS, Korkmaz S, Erkurt MA, Altuntaş F. Extracorporeal blood purification treatment options for COVID-19: the role of immunoadsorption. Transfus Apher Sci 2020;59;102855.
Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity 2016;49;472–9.
Bramlage CP, Schröder K, Bramlage P, Ahrens K, Zapf A, Müller GA, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher 2009;24;225–31.
Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005;9;391–5.
Balagholi S, Dabbaghi R, MousaviEshghi P. SA, Heshmati F, Mohammadi S. Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: immunopathogenesis and coagulopathy. Transfus Apher Sci 2020;59;102993.
Turgutkaya A, Yavaşoğlu İ, Bolaman Z Application of plasmapheresis for Covid-19 patients. Ther Apher Dial 2021;25;248–9.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Peer review under responsibility of the Dr. Sulaiman Al Habib Medical Group
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (https://doi.org/creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Alkattan, A., Oh-hashi, K. & Kandeel, M. Treatment Options during Cytokine Storm. Dr. Sulaiman Al Habib Med J 3, 48–52 (2021). https://doi.org/10.2991/dsahmj.k.210422.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/dsahmj.k.210422.001